Kalyoncu, U. Et Al. 2022. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clinical and experimental rheumatology , vol.40, no.11 , 2071-2077.

Kalyoncu, U., Bilgin, E., Erden, A., Satış, H., Tufan, A., Tekgöz, E., ... Ateş, A.(2022). Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clinical and experimental rheumatology , vol.40, no.11, 2071-2077.

Kalyoncu, Umut Et Al. "Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data," Clinical and experimental rheumatology , vol.40, no.11, 2071-2077, 2022

Kalyoncu, Umut Et Al. "Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data." Clinical and experimental rheumatology , vol.40, no.11, pp.2071-2077, 2022

Kalyoncu, U. Et Al. (2022) . "Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data." Clinical and experimental rheumatology , vol.40, no.11, pp.2071-2077.

@article{article, author={Umut Kalyoncu Et Al. }, title={Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data}, journal={Clinical and experimental rheumatology}, year=2022, pages={2071-2077} }